Loading...
XKRX
090370
Market cap17mUSD
Jul 09, Last price  
1,068.00KRW
1D
-1.29%
1Q
-24.20%
Jan 2017
-94.88%
IPO
-99.53%
Name

MetaLabs Co Ltd

Chart & Performance

D1W1MN
XKRX:090370 chart
P/E
—
P/S
0.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.32%
Rev. gr., 5y
-0.48%
Revenues
81.39b
+112.18%
96,691,754,000115,633,244,000127,014,045,000124,493,331,000151,702,804,810145,623,074,000141,412,155,020127,864,761,590115,996,783,08092,066,961,94026,832,431,61047,375,133,98086,896,351,29083,353,809,65039,300,730,76022,659,042,21021,598,887,65038,359,458,00081,390,341,000
Net income
-8.79b
L
11,167,976,0001,701,550,000-4,123,168,000-2,350,432,000478,478,000-26,417,144,000-11,079,980,270-4,037,119,140-36,710,092,120-39,219,756,780-37,939,377,530-13,521,275,940-25,362,334,390-19,340,233,270-16,200,774,560-12,812,632,080-7,299,953,580196,936,000-8,789,647,000
CFO
-2.50b
L-34.77%
-1,559,379,000-335,133,000-13,404,655,0002,222,974,000-4,021,706,910-8,870,478,8002,567,033,290-10,838,135,350-7,883,383,220-10,014,767,330-8,468,021,080-6,896,735,860-4,021,331,0201,363,610,6202,279,490,380447,640,150-49,571,895-3,827,454,000-2,496,726,000
Dividend
Dec 27, 201227.309 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Metalabs Co., Ltd. primarily engages in the supply of clothing across South Korea. Its operations are multifaceted, also encompassing the manufacturing and distribution of pharmaceutical drugs, medical devices, and masks. The company further dedicates efforts to developing peptide-based biotechnological products, providing medical management solutions, distributing cosmetics, and overseeing dating applications. Founded in 2000 and based in Seoul, South Korea, the entity was formerly known as Avista Inc. until it adopted the name Metalabs Co., Ltd. in April 2018.
URL
http://www.metalabs.co.kr/
IPO date
Dec 26, 2006
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT